First Horizon Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

First Horizon Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$6.16K	Hold	688	–	–	﹤0.01%	1803
2025 Q1	$5.16K	Hold	688	–	–	﹤0.01%	1799
2024 Q4	$5.17K	Hold	688	–	–	﹤0.01%	1794
2024 Q3	$5.23K	Hold	688	–	–	﹤0.01%	1786
2024 Q2	$4.25K	Hold	688	–	–	﹤0.01%	1800
2024 Q1	$3.5K	Hold	688	–	–	﹤0.01%	1895
2023 Q4	$4.12K	Hold	688	–	–	﹤0.01%	1847
2023 Q3	$4.87K	Hold	688	–	–	﹤0.01%	1754
2023 Q2	$4.84K	Hold	688	–	–	﹤0.01%	1800
2023 Q1	$5.74K	Buy	688 +343	+99%	+$3.3K	﹤0.01%	1762
2022 Q4	$3.96K	Hold	345	–	–	﹤0.01%	1855
2022 Q3	$4K	Buy	+345	New	+$4.44K	﹤0.01%	1808

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

First Horizon Advisors's BCRX Position: Q2 2025 in Review

First Horizon Advisors held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2025 at 688 shares worth $6.16K. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

First Horizon Advisors first reported a position in BCRX in Q3 2022 and has held it in 12 quarters since. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

First Horizon Advisors held 688 shares of BioCryst Pharmaceuticals worth $6.16K as of Q2 2025.
First Horizon Advisors left its BioCryst Pharmaceuticals share count unchanged in Q2 2025.
BioCryst Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1803 holding.
First Horizon Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.